# A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer

> **NCT07740720** · PHASE3 · NOT_YET_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 90 (estimated)

## Conditions studied

- Neoplasms, Rectal

## Interventions

- **BIOLOGICAL:** Dostarlimab

## Key facts

- **NCT ID:** NCT07740720
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-17
- **Primary completion:** 2029-12-12
- **Final completion:** 2029-12-31
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07740720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07740720, "A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07740720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*